Aspen API’s Green answer to peptide synthesis
Our Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS) combines the advantages of the classical solution-phase synthesis with the solid-phase approach.
Our green answer to peptide synthesis
We have developed a patented method for green and large-scale manufacturing of peptides in a solution called Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS). GC-LPPS combines the advantages of the classical solution-phase synthesis with the solid-phase approach. It is characterized by the fact that intermediates are not isolated. This enables a highly efficient synthesis method that is easy to scale up and yield products of reproducible high purity. Moreover, our GC-LPPS method uses green ethyl acetate as solvent, and only very low amounts of solvent are used with respect to solid-phase synthesis. International authorities approved our method. For many years, we produce on commercial scale for instance Leuprolide acetate with this method.
Focus on sustainability
Our focus on sustainability does not stop by having developed the GC-LPPS method. We are striving for optimization and are working on this in our labs. We also focus on waste water treatment, recovery of solvents, energy reduction, and several other examples in which we try to reduce our manufacturing footprint in the manufacturing of peptides. Besides the further optimization of the GC-LPPS method, we constantly put effort into minimizing the use of chemicals of very high concern in our other processes, e.g. the solvent DMF. We want to be pro-active and we want to be prepared for the future. By buying our API, our customers will receive a service level that completely unburdens them. From security to supply to helping pharmaceutical companies in achieving their sustainability goals.
Manufacturing facilities
At our site in Aspen Oss, the Netherlands, we have established approximately 50 years of experience and a solid reputation of producing cGMP peptides. Next to our proven capability in producing GC-LPPS peptides on commercial scale, we have extensive expertise and experience in both solution and solid-phase synthesis. Our cGMP production facilities are able to produce peptides from gram, to kilo, to tons to support clinical and commercial demands. All our facilities have been successfully inspected and approved by international health authorities, including the US FDA, EDQM, the Dutch Health authorities and PMDA, as well as by our customers.
Our C(D)MO offering in peptides
Our Aspen API team is passionate about molecules and we offer the power of expertise, innovation, compliance, registration and partnership to your project. With a heritage of nearly 100 years, we promise what we do and do what we promise. Whether your project is for a New Chemical Entity (NCE), or a process for (re-)designing your (intermediate) API into a green API, we will be your partner from the development phase to the commercial implementation. You will be working with a high-quality partner who offers skills and well-equipped pilot laboratories, pilot plants and cGMP facilities to enable development, efficient technology transfer and scale up of your API.
Related News
-
Sponsored Content CPHI Online Trend Report: How can flow chemistry help businesses achieve their sustainability goals?
In our latest CPHI Online Trend Report, we partner with Asymchem to understand the innovative potential of flow chemistry for API manufacturing, especially in regards to meeting sustainability goals. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
Sponsored Content Discover Our Organic Mineral Salts as APIs
Discover the range of organic mineral salts that serve as Active Pharmaceutical Ingredients available from Dr. Paul Lohmann®. -
Sponsored Content CPHI Podcast Series: Ursatec – celebrating 30 years of pioneering preservative free
In the latest episode of the CPHI Podcast Series, Digital Editor Lucy Chard spoke with Dominik Rocchi of Ursatec. -
Sponsored Content How healthcare trends inform dosage forms
Capsules encompass one of the most popular solid oral dosage forms for pharmaceutical products, with the global empty capsule market predicted to rise to USD $3.7 billion by 2026. The growth in the capsule market can be partly attributed to the many op... -
Sponsored Content Pharma Trend Outlook: Pharma 4.0 and Industry Resilience
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
Sponsored Content CPHI Podcast Series: Key Considerations in Selecting the Right CMO Partner
In this month's episode we hear from Jayna Blake, Senior Project Manager for Technical Programs at Baxter BioPharma Solutions, on key considerations for successful CMO selection. -
Sponsored Content Size doesn’t matter: How smaller deals are shaping healthcare M&A
Several mega-deals have made a splash in the pharma and life sciences industries over recent years – from AstraZeneca’s acquisition of Alexion for $39 billion to Gilead Sciences’ $21 billion purchase of Immunomedics. With am...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance